Pfizer will end development of daily weight-loss pill after liver injury
Pharmaceutical giant Pfizer stopped development of its weight-loss pill, danuglipron, after it discovered that one patient suffered potential liver issues.
← Back to stories
National16 articles from 12 sources across the spectrum· Updated 534d ago
8 across the spectrum · tap a section to jump
How each side is putting it
Left
2 viewpointsPfizer ends development of potential pill obesity treatment
Center
4 viewpointsRan by 4 outlets across the spectrum· WFMZ Allentown, WDIO Duluth
Ran by 6 outlets· NBC 5 Dallas-Fort Worth, NBC10 Philadelphia, +4 more
Pfizer Halts Development of Obesity Drug After Patient Sustains 'Liver Injury'
Right
2 viewpointsPfizer ends development of potential pill obesity treatment
Pfizer ends development of potential pill obesity treatment - The Daily Reporter
Pfizer will end development of daily weight-loss pill after liver injury